Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.

Min-Chan ParkHiroaki MatsunoJinseok KimSung-Hwan ParkSang-Heon LeeYong-Beom ParkYun Jong LeeSang-Il LeeWon ParkDong Hyuk SheenJung-Yoon ChoeChan-Bum ChoiSeung-Jae HongChang-Hee SuhShin-Seok LeeHoon-Suk ChaBin YooJin-Wuk HurGeun-Tae KimWan-Hee YooHan Joo BaekKichul ShinSeung Cheol ShimHyung-In YangHyun Ah KimKyung-Su ParkIn Ah ChoiJisoo LeeMasato TomomitsuSeonghye ShinJiyoon LeeYeong-Wook Song

Published in: Arthritis research & therapy (2019)

ClinicalTrials.gov, NCT02715908 . Registered 22 March 2016.

Keyphrases

phase iii
double blind
placebo controlled
rheumatoid arthritis
clinical trial
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
open label
phase ii
study protocol
disease activity
medical education
randomized controlled trial
systemic lupus erythematosus